PMID: 20127551Feb 4, 2010Paper

European Society of Gene & Cell Therapy--17th annual congress

IDrugs : the Investigational Drugs Journal
Marinee Chuah

Abstract

The 17th Annual Congress of the European Society of Gene & Cell Therapy, held in Hanover, Germany, included topics covering new developments in the field of stem cell therapy. This conference report highlights selected presentations on stem cell gene therapy and the use of stem cells in regenerative medicine. Investigational therapies discussed include Lenti-D (Genetix Pharmaceuticals Inc/INSERM) and LentiGlobin (Genetix), a lentiviral vector-based gene transfer system containing either a human beta-globin gene or a hybrid A-gamma/beta-globin gene.

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.